Umeå University's logo

umu.sePublications
Change search
Refine search result
1234567 1 - 50 of 433
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Adey, Brett N.
    et al.
    Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.
    Cooper-Knock, Johnathan
    Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom.
    Al Khleifat, Ahmad
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.
    Fogh, Isabella
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.
    van Damme, Philip
    Department of Neurosciences, KU Leuven-University of Leuven, Experimental Neurology, Leuven Brain Institute (LBI), Leuven, Belgium; VIB, Center for Brain and Disease Research, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
    Corcia, Philippe
    UMR 1253, Université de Tours, Inserm, Tours, France; Centre de référence sur la SLA, CHU de Tours, Tours, France.
    Couratier, Philippe
    Centre de référence sur la SLA, CHRU de Limoges, Limoges, France; UMR 1094, Université de Limoges, Inserm, Limoges, France.
    Hardiman, Orla
    Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
    McLaughlin, Russell
    Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
    Gotkine, Marc
    Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah Medical Center, Jerusalem, Israel.
    Drory, Vivian
    Department of Neurology, Tel-Aviv Sourasky Medical Centre, Tel-Aviv, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
    Silani, Vincenzo
    Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy; Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, Milan, Italy.
    Ticozzi, Nicola
    Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy; Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, Milan, Italy.
    Veldink, Jan H.
    Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.
    van den Berg, Leonard H.
    Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.
    de Carvalho, Mamede
    Instituto de Fisiologia, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
    Pinto, Susana
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences. Instituto de Fisiologia, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
    Mora Pardina, Jesus S.
    ALS Unit, Hospital San Rafael, Madrid, Spain.
    Povedano Panades, Mónica
    Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, Barcelona, L’Hospitalet de Llobregat, Spain.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Weber, Markus
    Neuromuscular Diseases Unit/ALS Clinic, St. Gallen, Switzerland.
    Başak, Nazli A.
    Koc University School of Medicine, Translational Medicine Research Center, NDAL, Istanbul, Turkey.
    Shaw, Christopher E.
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.
    Shaw, Pamela J.
    Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom.
    Morrison, Karen E.
    School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom.
    Landers, John E.
    Department of Neurology, University of Massachusetts Medical School, MA, Worcester, United States.
    Glass, Jonathan D.
    Department of Neurology, Emory University School of Medicine, GA, Atlanta, United States.
    Vourc’h, Patrick
    Department of Neurology, University Hospitals Leuven, Leuven, Belgium; Service de Biochimie et Biologie molécularie, CHU de Tours, Tours, France.
    Dobson, Richard J. B.
    Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom; National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London, Maudsley NHS Foundation Trust, King’s College London, London, United Kingdom; Institute of Health Informatics, University College London, London, United Kingdom; NIHR Biomedical Research Centre at University College London Hospitals, NHS Foundation Trust, London, United Kingdom.
    Breen, Gerome
    Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.
    Al-Chalabi, Ammar
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom; King’s College Hospital, London, United Kingdom.
    Jones, Ashley R.
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.
    Iacoangeli, Alfredo
    Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom; National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London, Maudsley NHS Foundation Trust, King’s College London, London, United Kingdom.
    Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival2023In: Frontiers in Cellular Neuroscience, E-ISSN 1662-5102, Vol. 17, article id 1112405Article in journal (Refereed)
    Abstract [en]

    Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/2 enhancers, which reduce gene expression and lead to disruption of membrane lipid rafts.

    Methods: Using large ALS whole-genome sequencing and post-mortem RNA sequencing datasets (5,987 and 365 tissue samples, respectively), and iPSC-derived motor neurons from 55 individuals, we investigated the role of CAV1/2 expression and enhancer variants in the ALS phenotype.

    Results: We report a differential expression analysis between ALS cases and controls for CAV1 and CAV2 genes across various post-mortem brain tissues and three independent datasets. CAV1 and CAV2 expression was consistently higher in ALS patients compared to controls, with significant results across the primary motor cortex, lateral motor cortex, and cerebellum. We also identify increased survival among carriers of CAV1/2 enhancer mutations compared to non-carriers within Project MinE and slower progression as measured by the ALSFRS. Carriers showed a median increase in survival of 345 days.

    Discussion: These results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS. We propose that carriers of CAV1/2 enhancer mutations may be conceptualised as an ALS subtype who present a less severe ALS phenotype with a longer survival duration and slower progression. Upregulation of CAV1/2 genes in ALS cases may indicate a causal pathway or a compensatory mechanism. Given prior research supporting the beneficial role of CAV1/2 expression in ALS patients, we consider a compensatory mechanism to better fit the available evidence, although further investigation into the biological pathways associated with CAV1/2 is needed to support this conclusion.

    Download full text (pdf)
    fulltext
  • 2.
    af Bjerkén, Sara
    et al.
    Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB). Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Axelsson, Jan
    Umeå University, Faculty of Medicine, Department of Radiation Sciences, Radiation Physics. Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI).
    Larsson, Anne
    Umeå University, Faculty of Medicine, Department of Radiation Sciences, Diagnostic Radiology.
    Flygare, Carolina
    Umeå University, Faculty of Medicine, Department of Radiation Sciences, Diagnostic Radiology.
    Remes, Jussi
    Umeå University, Faculty of Medicine, Department of Radiation Sciences, Diagnostic Radiology.
    Strandberg, Sara
    Umeå University, Faculty of Medicine, Department of Radiation Sciences, Diagnostic Radiology.
    Eriksson, Linda
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Bäckström, David C.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Jakobson Mo, Susanna
    Umeå University, Faculty of Medicine, Department of Radiation Sciences, Diagnostic Radiology. Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI).
    Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease2023In: Nuclear medicine communications, ISSN 0143-3636, E-ISSN 1473-5628, Vol. 44, no 5, p. 397-406Article in journal (Refereed)
    Abstract [en]

    Objective: [18F]FE-PE2I (FE-PE2I) is a new radiotracer for dopamine transporter (DAT) imaging with PET. The aim of this study was to evaluate the visual interpretation of FE-PE2I images for the diagnosis of idiopathic Parkinsonian syndrome (IPS). The inter-rater variability, sensitivity, specificity, and diagnostic accuracy for visual interpretation of striatal FE-PE2I compared to [123I]FP-CIT (FP-CIT) single-photon emission computed tomography (SPECT) was evaluated.

    Methods: Thirty patients with newly onset parkinsonism and 32 healthy controls with both an FE-PE2I and FP-CIT were included in the study. Four patients had normal DAT imaging, of which three did not fulfil the IPS criteria at the clinical reassessment after 2 years. Six raters evaluated the DAT images blinded to the clinical diagnosis, interpreting the image as being ‘normal’ or ‘pathological’, and assessed the degree of DAT-reduction in the caudate and putamen. The inter-rater agreement was assessed with intra-class correlation and Cronbach’s α. For calculation of sensitivity and specificity, DAT images were defined as correctly classified if categorized as normal or pathological by ≥4/6 raters.

    Results: The overall agreement in visual evaluation of the FE-PE2I- and FP-CIT images was high for the IPS patients (α = 0.960 and 0.898, respectively), but lower in healthy controls (FE-PE2I: α = 0.693, FP-CIT: α = 0.657). Visual interpretation gave high sensitivity (both 0.96) but lower specificity (FE-PE2I: 0.86, FP-CIT: 0.63) with an accuracy of 90% for FE-PE2I and 77% for FP-CIT.

    Conclusion: Visual evaluation of FE-PE2I PET imaging demonstrates high reliability and diagnostic accuracy for IPS.

  • 3.
    Ahlenhed, Valdemar
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Risk and predictive factors for poststroke epilepsy - Risk- och prediktiva faktorer för poststroke epilepsi2020Independent thesis Basic level (professional degree), 20 credits / 30 HE creditsStudent thesis
  • 4.
    Aineskog, Helena
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Baldvinsdóttir, Bryndís
    Department of Clinical Sciences - Neurosurgery, Lund University, Lund, Sweden.
    Ronne Engström, Elisabeth
    Department of Medical Sciences, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
    Eneling, Johanna
    Department of Clinical Sciences, Linköping University, Linköping, Sweden.
    Enblad, Per
    Department of Medical Sciences, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
    Svensson, Mikael
    Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
    Alpkvist, Peter
    Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
    Fridriksson, Steen
    Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden.
    Klurfan, Paula
    Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden.
    Hillman, Jan
    Department of Clinical Sciences, Linköping University, Linköping, Sweden.
    Kronvall, Erik
    Department of Clinical Sciences - Neurosurgery, Lund University, Lund, Sweden.
    Nilsson, Ola G.
    Department of Clinical Sciences - Neurosurgery, Lund University, Lund, Sweden.
    Lindvall, Peter
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    A national cohort with aneurysmal subarachnoid hemorrhage: patient characteristics, choice of treatment, clinical outcome, and factors of prognostic importance2024In: World Neurosurgery, ISSN 1878-8750, E-ISSN 1878-8769, Vol. 190, p. e513-e524Article in journal (Refereed)
    Abstract [en]

    Objective: To study associations of clinical characteristics and treatment choice with functional outcome, mortality, and time to death in a national sample of aneurysmal subarachnoidal hemorrhage patients.

    Methods: Data were extracted from a prospective nationwide multicenter study performed in September 2014 to March 2018. Glasgow Outcome Scale Extended (GOSE) grade, 1-year mortality, and survival probability were assessed at one year after ictus. Logistic univariate, multivariate, and Cox regression analyses were used to study the variables' associations with the outcomes.

    Results: Unfavorable dichotomized GOSE (dGOSE; grades 1–4) was observed in 35.4% of patients. Microsurgery was preferred for middle cerebral artery aneurysms and Fisher grade 4. Treatment modality was not associated with any outcome measure. Dichotomized World Federation of Neurosurgical Societies (dWFNS), age, and delayed ischemic neurological deficit (DIND) showed significant correlations with dGOSE and 1-year mortality in multivariate regression analyses. Pupil dilatation was associated with a 1-year mortality outcome. Cox regression analysis showed lower survival probability for pupil dilatation (hazard ratio [HR]: 3.546), poor dWFNS (HR: 3.688), higher age (HR: 1.051), and DIND occurrence (HR: 2.214).

    Conclusions: The patient selection in Sweden after aneurysmal subarachnoidal hemorrhage showed similar values for dGOSE, 1-year mortality, and survival probability between patients treated with microsurgery or endovascular technique. Poor dWFNS, higher age, and DIND were significantly associated with unfavorable dGOSE, mortality, and survival probability. Pupil dilatation was significantly associated with mortality and survival probability.

    Download full text (pdf)
    fulltext
  • 5.
    Aineskog, Helena
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Johansson, Conny
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Nilsson, Robert
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Koskinen, Lars-Owe D.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Lindvall, Peter
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Serum S100B correlates with health-related quality of life and functional outcome in patients at 1 year after aneurysmal subarachnoid haemorrhage2022In: Acta Neurochirurgica, ISSN 0001-6268, E-ISSN 0942-0940, Vol. 164, no 8, p. 2209-2218Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Early, objective prognostication after aneurysmal subarachnoid haemorrhage (aSAH) is difficult. A biochemical marker would be desirable. Correlation has been found between levels of the protein S100 beta (S100B) and outcome after aSAH. Timing and clinical usefulness are under investigation.

    METHODS: Eighty-nine patients admitted within 48 h of aSAH were included. Modified ranking scale (mRS), EuroQoL health-related quality of life measure (EQ-5Dindex) and EuroQoL visual analogue scale (EQ-VAS) values were evaluated after 1 year. S100B was measured in blood samples collected at admission and up to day 10.

    RESULTS: S100B correlated significantly with EQ-5Dindex and mRS, but not EQ-VAS at 1 year after aSAH. A receiver operating characteristic analysis for peak S100B values (area under the curve 0.898, 95% confidence interval 0.828-0.968, p < 0.0001), with a cutoff of 0.4 μg/l, yielded 95.3% specificity and 68% sensitivity for predicting unfavourable outcome. Dichotomized S100B (> 0.4 μg/l vs ≤ 0.4 μg/l), age and Hunt and Hess grading scale score (HH) were associated with unfavourable mRS outcome in univariate logistic regression analysis. Dichotomized S100B was the only variable independently correlated with unfavourable mRS outcome in a multivariate logistic regression analysis.

    CONCLUSIONS: For the first time, S100B was shown to correlate with mRS and health-related quality of life at 1 year after aSAH. Peak S100B can be used as a prognostic factor for unfavourable outcome measured as dichotomized mRS after aSAH. A peak value cutoff of 0.4 μg/l is suggested. Ethical approval no: 2013/366-31, 4th of February 2014.

    Download full text (pdf)
    fulltext
  • 6.
    Ajobi, Faisal Farhan
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Tidig neuroinflammation och prognosen i Parkinsonssjukdom2022Independent thesis Basic level (professional degree), 20 credits / 30 HE creditsStudent thesis
  • 7.
    Alonso-Magdalena, Lucía
    et al.
    Department of Neurology, Skåne University Hospital and Department of Clinical Sciences, Lund University, Lund, Sweden.
    Carmona i Codina, Olga
    Department of Neurology, Fundacio Salut Emporda, Figueres and Department of Clinical Sciences, Faculty of Medicine, Girona University, Spain.
    Zia, Elisabet
    Department of Clinical Sciences, Lund University, Malmö, Sweden.
    Sundström, Peter
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Pessah-Rasmussen, Hélène
    Department of Rehabilitation medicine, Skåne University Hospital and Department of Clinical Sciences, Lund University, Lund, Sweden.
    Prevalence and disease disability in immigrants with multiple sclerosis in Malmö, southern Sweden2024In: Clinical neurology and neurosurgery, ISSN 0303-8467, E-ISSN 1872-6968, Vol. 240, article id 108255Article in journal (Refereed)
    Abstract [en]

    Background: Multiple sclerosis (MS) is the most common chronic demyelinating disease of the central nervous system and the major non-traumatic cause of permanent disability in young adults. Several migration studies have been performed over the years suggesting a pattern of higher disease disability in certain ethnic groups. To our knowledge, differences in disease progression in immigrants have not been studied in Sweden before. Thus, the aims of our study were to estimate the prevalence of multiple sclerosis among first-generation immigrants in the City of Malmö and to compare differences in disease severity with the native population.

    Methods: All persons with multiple sclerosis living in Malmö on prevalence day 31 Dec 2010 were included. Cases were classified according to the country of birth into Scandinavians, Western and non-Western.

    Results: The crude prevalence was 100/100,000 (95% CI, 80–124) among first-generation immigrants, 154/100,000 (95% CI, 137–173) among individuals with Scandinavian background, 123/100,000 (95% CI, 94–162) in the Western group and 76/100,000 (95% CI, 53–108) in the non-Western group. The mean Multiple Sclerosis Severity Score (MSSS) value among Scandinavians was 4.2 (SD 3.5), whereas the figures in the immigrant group were 4.6 (SD 3.3) and 5.2 (SD 3.7) among Westerns respectively non-Westerns, which differences were not statistically significant. When adjusting for gender, age at onset and initial disease course, the mean MSSS difference between the non-Western and the Scandinavian individuals was 1.7 (95% CI 0.18–3.3, p = 0.030). There were no differences on time to diagnosis or the time from diagnosis to treatment initiation between the three groups.

    Conclusions: We found a lower prevalence among Western and non-Western first-generation immigrants compared to the Scandinavian population and a more severe disease in non-Western immigrants than in Scandinavians.

    Download full text (pdf)
    fulltext
  • 8. Alonso-Magdalena, Lucía
    et al.
    Zia, Elisabet
    Carmona I Codina, Olga
    Pessah-Rasmussen, Hélène
    Sundström, Peter
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Incidence and prevalence of multiple sclerosis in Malmö, southern Sweden2022In: Multiple Sclerosis International, ISSN 2090-2654, E-ISSN 2090-2662, article id 5464370Article in journal (Refereed)
    Abstract [en]

    OBJECTIVES: To estimate the incidence and prevalence of multiple sclerosis (MS) in Malmö municipality in southwestern Sweden.

    MATERIALS AND METHODS: Multiple sources were used in the case identification process. Case ascertainment was assessed by medical chart review including examinations such as magnetic resonance imaging, cerebrospinal fluid analyses, and relevant laboratory tests. Cases were classified according to the 2010 McDonald's diagnostic criteria. Onset-adjusted prevalence and a definition of onset symptoms were applied.

    RESULTS: The crude incidence of MS in 2001-2010 in Malmö municipality was 5.3/100,000 (95% confidence interval (CI): 4.5 to 6.2). There was a relapsing onset in 90.5% of cases. The female to male ratio was 1.8. The onset-adjusted prevalence for Dec 2010 was 133/100,000 (95% CI, 120 to 146) with a female to male ratio of 2.1.

    CONCLUSIONS: This is the first population-based epidemiological study in Skåne, the most southwestern part of Sweden showing a high incidence and prevalence. We found a lower incidence than expected according to previous nationwide figures, probably due to methodological differences between the studies. Our findings support the presence of a north-south gradient of MS prevalence in Sweden.

    Download full text (pdf)
    fulltext
  • 9. Andelic, Nada
    et al.
    Røe, Cecilie
    Brunborg, Cathrine
    Zeldovich, Marina
    Løvstad, Marianne
    Løke, Daniel
    Borgen, Ida M.
    Voormolen, Daphne C.
    Howe, Emilie I.
    Forslund, Marit V.
    Dahl, Hilde M.
    von Steinbuechel, Nicole
    Koskinen, Lars-Owe (Contributor)
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Frequency of fatigue and its changes in the first 6 months after traumatic brain injury: results from the CENTER-TBI study2021In: Journal of Neurology, ISSN 0340-5354, E-ISSN 1432-1459, Vol. 268, no 1, p. 61-73Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Fatigue is one of the most commonly reported subjective symptoms following traumatic brain injury (TBI). The aims were to assess frequency of fatigue over the first 6 months after TBI, and examine whether fatigue changes could be predicted by demographic characteristics, injury severity and comorbidities.

    METHODS: Patients with acute TBI admitted to 65 trauma centers were enrolled in the study Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI). Subjective fatigue was measured by single item on the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), administered at baseline, three and 6 months postinjury. Patients were categorized by clinical care pathway: admitted to an emergency room (ER), a ward (ADM) or an intensive care unit (ICU). Injury severity, preinjury somatic- and psychiatric conditions, depressive and sleep problems were registered at baseline. For prediction of fatigue changes, descriptive statistics and mixed effect logistic regression analysis are reported.

    RESULTS: Fatigue was experienced by 47% of patients at baseline, 48% at 3 months and 46% at 6 months. Patients admitted to ICU had a higher probability of experiencing fatigue than those in ER and ADM strata. Females and individuals with lower age, higher education, more severe intracranial injury, preinjury somatic and psychiatric conditions, sleep disturbance and feeling depressed postinjury had a higher probability of fatigue.

    CONCLUSION: A high and stable frequency of fatigue was found during the first 6 months after TBI. Specific socio-demographic factors, comorbidities and injury severity characteristics were predictors of fatigue in this study.

    Download full text (pdf)
    fulltext
  • 10.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences. Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Amyotrophic lateral sclerosis and CuZn-superoxide dismutase: a clinical, genetic and enzymatic study1997Doctoral thesis, comprehensive summary (Other academic)
  • 11.
    Andersen, Peter M.
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Forsgren, Lars
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Binzer, M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Nilsson, P.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Ala-Hurula, V.
    Keränen, M.-L.
    Bergmark, L.
    Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neurophysiology.
    Saarinen, A.
    Haltia, T.
    Tarvainen, I.
    Kinnunen, E.
    Udd, B.
    Marklund, Stefan L.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation: a clinical and genealogical study of 36 patients1996In: Brain, ISSN 0006-8950, E-ISSN 1460-2156, Vol. 119, p. 1153-1172Article in journal (Refereed)
  • 12.
    Andersen, Peter M.
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Kuźma-Kozakiewicz, Magdalena
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland; Neurodegenerative Diseases Research Group, Medical University of Warsaw, Warsaw, Poland.
    Keller, Jürgen
    Department of Neurology, University of Ulm, Ulm, Germany.
    Maksymowicz-Śliwińska, Anna
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
    Barć, Krzysztof
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
    Nieporęcki, Krzysztof
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
    Finsel, Julia
    Department of Neurology, University of Ulm, Ulm, Germany.
    Vazquez, Cynthia
    Department of Neurology, University of Ulm, Ulm, Germany.
    Helczyk, Olga
    Department of Neurology, University of Ulm, Ulm, Germany.
    Linse, Katharina
    Department of Neurology, Technische Universität Dresden, and German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.
    Häggström, Ann-Cristin E.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Stenberg, Erica
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Semb, Olof
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Professional Development.
    Ciećwierska, Katarzyna
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
    Szejko, Natalia
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
    Uttner, Ingo
    Department of Neurology, University of Ulm, Ulm, Germany.
    Herrmann, Andreas
    Department of Neurology, Technische Universität Dresden, and German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.
    Petri, Susanne
    Department of Neurology, Hannover Medical School, Hannover, Germany.
    Meyer, Thomas
    Department of Neurology, Charité CVK, Berlin, Germany.
    Ludolph, Albert C.
    Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.
    Lulé, Dorothée
    Department of Neurology, University of Ulm, Ulm, Germany.
    Caregivers’ divergent perspectives on patients’ well-being and attitudes towards hastened death in Germany, Poland and Sweden2022In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, ISSN 2167-8421, E-ISSN 2167-9223, Vol. 23, no 3-4, p. 252-262Article in journal (Refereed)
    Abstract [en]

    Background: During the course of amyotrophic lateral sclerosis (ALS), patients and their families are faced with existential decisions concerning life-prolonging and -shortening measures. Correct anticipation of patient’s well-being and preferences is a prerequisite for patient-centered surrogate decision making.

    Methods: In Germany (N = 84), Poland (N = 77) and Sweden (N = 73) patient-caregiver dyads were interviewed. Standardized questionnaires on well-being (ADI-12 for depressiveness; ACSA for global quality of life) and wish for hastened death (SAHD) were used in ALS patients. Additionally, caregivers were asked to fill out the same questionnaires by anticipating patients’ perspective (surrogate perspective).

    Results: Caregivers significantly underestimated patients’ well-being in Germany and Poland. For Swedish caregivers, there were just as many who underestimated and overestimated well-being. The same was true for wish for hastened death in all three countries. For Swedish and Polish patients, caregivers’ estimation of well-being was not even associated with patients’ responses and the same was true for estimation of wish for hastened death in all three countries. Older caregivers and those with the most frequent encounter with the patient were the closest in their rating of well-being and wish for hastened death to the patients’ actual state, while caregivers with chronic disease him/herself were more likely to underestimate patient’s well-being.

    Discussion: Despite distinct cultural differences, there was a clear discrepancy between patients’ and caregivers’ perspective on patients’ well-being and preferences towards life in all three countries. This possible bias in caregivers’ judgment needs to be taken into account in surrogate decision making.

  • 13.
    Andersen, Peter M.
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences. Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Nilsson, P.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Forsgren, Lars
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Marklund, Stefan L.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    CuZn-superoxide dismutase, extracellular superoxide dismutase, and glutathione peroxidase in blood from individuals homozygous for ASP90ALA CuZn-superoxide dismutase mutation1998In: Journal of Neurochemistry, ISSN 0022-3042, E-ISSN 1471-4159, Vol. 70, no 2, p. 715-720Article in journal (Refereed)
  • 14.
    Andersen, Peter M.
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences. Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Nilsson, P.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Keränen, M.-L.
    Forsgren, Lars
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Hägglund, J.
    Karlsborg, M.
    Ronnevi, L.-O.
    Gredal, O.
    Marklund, Stefan L.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia1997In: Brain, ISSN 0006-8950, E-ISSN 1460-2156, Vol. 120, no 10, p. 1723-1737Article in journal (Refereed)
  • 15.
    Andersen, Peter M.
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences. Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Nilsson, Peter
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Ala-Hurula, Veli
    Keränen, Marja-Leena
    Tarvainen, Ilkka
    Haltia, Tuula
    Nilsson, Lotta
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Binzer, Michael
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Forsgren, Lars
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Marklund, Stefan L.
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
    Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase1995In: Nature Genetics, ISSN 1061-4036, E-ISSN 1546-1718, Vol. 10, p. 61-66Article in journal (Refereed)
  • 16.
    Andersen, Peter Munch
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Extensive heterogeneity in patients with ALS with mutations in SOD1 in France2021In: Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, E-ISSN 1468-330X, Vol. 92, no 9, p. 914-914Article in journal (Other academic)
  • 17.
    Andersson, Johanna
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Idiopathic normal pressure hydrocephalus: epidemiology and diagnostics2021Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Idiopathic normal pressure hydrocephalus (iNPH) is a progressive neurological condition characterized by a deterioration of gait, cognition, and continence. The diagnosis is based on a combination of enlarged ventricles seen in neuroimaging, with typical clinical findings. iNPH often affects elderly individuals (i.e., over the age of 65). Shunt insertion is the only available treatment, with an improvement rate of up to 80%.

    The prevalence has previously been reported to be between 0.5 and 3% among individuals over age 65. However, most previous studies have been conducted on hospital-based materials, and there is a lack of epidemiological studies based on the general population. One of the challenges of diagnosing iNPH is that there are no common, widely accepted diagnostic criteria. There are currently two different diagnostic guidelines: the American-European guidelines and the Japanese ones, which makes it harder to compare different studies.

    The aim of this thesis was to determine the prevalence of iNPH in population-based materials and to evaluate the differences between the diagnostic guidelines. Furthermore, we wanted to assess the quality of life and depressive symptoms among individuals with iNPH compared to those without. In addition, we assessed longitudinal changes in the clinical and radiological findings of iNPH.

    We asked 1,000 individuals aged 65 and older to participate in the study by answering a questionnaire containing typical iNPH symptoms. We invited all participants who had marked at least two symptoms on the questionnaire for further investigation, in addition to a randomly selected group with fewer than two symptoms. A total of 168 participants underwent clinical examinations and computed tomography (CT) of the brain. We followed up with the same cohort two years later with repeated testing, with the addition of questionnaires on depressive symptoms and quality of life. A total of 122 individuals remained in the 2-year follow-up cohort. The clinical examinations included an iNPH-specific grading scale for symptoms and neurological examinations.

    The prevalence of iNPH for those 65 years and older was 3.7% according to the American-European guidelines and 1.5% according to the Japanese guidelines. The prevalence was higher for those over age 80, with no differences between the sexes. Furthermore, participants with iNPH had more depressive symptoms and lower quality of life than those without iNPH. Radiological findings and symptoms progressed slightly over two years, and those with symptom deterioration had an even higher degree of radiological progress compared to those with stationary or improved symptoms.

    This thesis shows that iNPH is fairly common in a normal population of elderly individuals. There is disagreement between the current diagnostic guidelines, which underscores the need for revisions, preferably into one common diagnostic system. In this thesis, individuals with iNPH had a lower functional status, more depressive symptoms, and lower quality of life than those without iNPH.

    Moreover, iNPH progresses slightly in both symptoms and radiological signs over two years, which underlines the value of clinical follow-up for asymptomatic individuals with radiological signs of iNPH. Finally, iNPH is probably underdiagnosed and an important diagnosis to consider in an elderly person with gait and balance impairments.

    Download full text (pdf)
    fulltext
    Download (pdf)
    spikblad
    Download (png)
    presentationsbild
    Download (pdf)
    errata
  • 18.
    Andersson, Johanna
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Rosell, M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Kockum, Karin
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Söderström, Lars
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Laurell, Katarina
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Challenges in diagnosing normal pressure hydrocephalus: evaluation of the diagnostic guidelines2017In: eNeurologicalSci, ISSN 2405-6502, Vol. 7, p. 27-31Article in journal (Refereed)
    Abstract [en]

    Purpose: To evaluate the present diagnostic guidelines of idiopathic normal pressure hydrocephalus (iNPH) in a sample from the general population.

    Methods: A total of 168 individuals (93 females, 75 males), mean age 75 years (range 66-92) with and without symptoms of iNPH underwent a CT-scan of the brain, a neurological examination with assessment of the triad symptoms, i.e. gait disturbances, memory impairment and urgency incontinence. The participants were then diagnosed as "unlikely", "possible" and "probable" iNPH according to the American-European and the Japanese guidelines, respectively. Separately, a senior consultant in neurology diagnosed each patient based on the overall clinical picture.

    Results: Obtaining a diagnosis of "probable iNPH" was three times more likely according to the American-European guidelines (n = 35) compared to the Japanese guidelines (n = 11) or the neurologist (n = 11). The concordance was highest (Kappa = 0.69) between the Japanese guidelines and the neurologist.

    Conclusions: Considerable discrepancies were found when diagnosing iNPH according to two international guidelines and a neurologist, respectively. The Japanese guidelines, which include a minimum of two triad symptoms, were most concordant with the neurologist. As a step towards widely accepted, standardized diagnostic criteria, we suggest a revision of the current guidelines, preferably into one common diagnostic system.

    Download full text (pdf)
    fulltext
  • 19. Arango-Lasprilla, Juan Carlos
    et al.
    Zeldovich, Marina
    Olabarrieta-Landa, Laiene
    Vindal Forslund, Marit
    Núñez-Fernández, Silvia
    von Steinbuechel, Nicole
    Isager Howe, Emilie
    Røe, Cecilie
    Andelic, Nada
    Koskinen, Lars-Owe D. (Contributor)
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Sundström, Nina (Contributor)
    Umeå University, Faculty of Medicine, Department of Radiation Sciences.
    Early Predictors of Employment Status One Year Post Injury in Individuals with Traumatic Brain Injury in Europe2020In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 9, no 6, article id 2007Article in journal (Refereed)
    Abstract [en]

    Sustaining a traumatic brain injury (TBI) often affects the individual’s ability to work, reducing employment rates post-injury across all severities of TBI. The objective of this multi-country study was to assess the most relevant early predictors of employment status in individuals after TBI at one-year post-injury in European countries. Using a prospective longitudinal non-randomized observational cohort (The Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) project), data was collected between December 2014–2019 from 63 trauma centers in 18 European countries. The 1015 individuals who took part in this study were potential labor market participants, admitted to a hospital and enrolled within 24 h of injury with a clinical TBI diagnosis and indication for a computed tomography (CT) scan, and followed up at one year. Results from a binomial logistic regression showed that older age, status of part-time employment or unemployment at time of injury, premorbid psychiatric problems, and higher injury severity (as measured with higher Injury severity score (ISS), lower Glasgow Coma Scale (GCS), and longer length of stay (LOS) in hospital) were associated with higher unemployment probability at one-year after injury. The study strengthens evidence for age, employment at time of injury, premorbid psychiatric problems, ISS, GCS, and LOS as important predictors for employment status one-year post-TBI across Europe.

    Download full text (pdf)
    fulltext
  • 20.
    Arvidsson, Sandra
    et al.
    Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences. Umeå University, Faculty of Medicine, Department of Clinical Microbiology.
    Eriksson, Robert
    Clinical Neurophysiology, Umeå University Hospital, Umeå, Sweden.
    Anan, Intissar
    Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine. Umeå University, Faculty of Medicine, Wallenberg Centre for Molecular Medicine at Umeå University (WCMM).
    Heldestad, Victoria
    Umeå University, Faculty of Medicine, Department of Clinical Microbiology. Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Enlarged cross-sectional area in peripheral nerves in Swedish patients with hereditary V30M transthyretin amyloidosis2023In: Annals of Medicine, ISSN 0785-3890, E-ISSN 1365-2060, Vol. 55, no 2, article id 2239269Article in journal (Refereed)
    Abstract [en]

    Introduction: In hereditary transthyretin amyloidosis (ATTRv), two different fibrillar forms causing the amyloid deposition, have been identified, displaying substantially cardiac or neuropathic symptoms. Neuropathic symptoms are more frequent in early-onset patients, whereas late-onset patients, besides cardiac symptoms, seem to develop carpal tunnel syndrome, more often. With ultrasonography (US) of peripheral nerves, it is possible to distinguish structural changes, and enlarged cross-sectional area (CSA). The main purpose of this study was, for the first time, to elucidate US of peripheral nerves in Swedish ATTRv patients at an early stage of the disease, and to evaluate possible early enlarged CSA.

    Material and methods: This prospective study included first visit data of 13 patients, aged 30–88 years, of which 11 with late-onset age. All had a positive V30M mutation. Eight men and six women (aged 28–74 years) served as controls.

    Results: Significantly enlarged CSA was seen in ATTRv patients for the tibial nerve at the ankle (p =.001), the sural nerve (p <.001), the peroneal nerve at the popliteal fossa (p =.003), and the ulnar nerve at the middle upper arm (p =.007).

    Conclusion: US of peripheral nerves could be a valuable tool in disease evaluation and could facilitate monitoring of disease progression.

    Download full text (pdf)
    fulltext
  • 21.
    Atterling Brolin, Kajsa
    et al.
    Translational Neurogenetics Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden; Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
    Bäckström, David
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Wallenius, Joel
    Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden.
    Gan-Or, Ziv
    Department of Neurology & Neurosurgery, McGill University, QC, Montreal, Canada; Clinical Research Unit, The Neuro (Montreal Neurological Institute-Hospital), QC, Montreal, Canada; Department of Human Genetics, McGill University, QC, Montreal, Canada.
    Puschmann, Andreas
    Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden; SciLifeLab National Research Infrastructure, Lund University, Sweden.
    Hansson, Oskar
    Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
    Swanberg, Maria
    Translational Neurogenetics Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.
    GBA1 T369M and Parkinson's disease - Further evidence of a lack of association in the Swedish population2025In: Parkinsonism & Related Disorders, ISSN 1353-8020, E-ISSN 1873-5126, Vol. 130, article id 107191Article in journal (Refereed)
    Abstract [en]

    Variants in GBA1 are important genetic risk factors in Parkinson's disease (PD). GBA1 T369M has been linked to an ∼80 % increased PD risk but the reports are conflicting and the relevance of GBA1 variants in different populations varies. A lack of association between T369M and PD in the Swedish population was recently reported but needs further validation. We therefore investigated T369M in 1,808 PD patients and 2,183 controls and our results support that T369M is not a risk factor for PD in the Swedish population.

    Download full text (pdf)
    fulltext
  • 22.
    Awad, Amar
    et al.
    Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI). Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB), Physiology.
    Grill, Filip
    Umeå University, Faculty of Medicine, Department of Radiation Sciences. Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI).
    Blomstedt, Patric
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Nyberg, Lars
    Umeå University, Faculty of Medicine, Department of Radiation Sciences. Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI). Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB), Physiology.
    Eriksson, Johan
    Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB), Physiology. Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI).
    Deep brain stimulation does not modulate fMRI resting- state functional connectivity in essential tremorManuscript (preprint) (Other academic)
  • 23.
    Awad, Amar
    et al.
    Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI). Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB), Physiology.
    Grill, Filip
    Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI). Umeå University, Faculty of Medicine, Department of Radiation Sciences.
    Blomstedt, Patric
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Nyberg, Lars
    Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI). Umeå University, Faculty of Medicine, Department of Radiation Sciences. Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB), Physiology.
    Eriksson, Johan
    Umeå University, Faculty of Medicine, Umeå Centre for Functional Brain Imaging (UFBI). Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB), Physiology.
    Deep brain stimulation does not modulate resting-state functional connectivity in essential tremor2024In: Brain Communications, E-ISSN 2632-1297, Vol. 6, no 2, article id fcae012Article in journal (Refereed)
    Abstract [en]

    While the effectiveness of deep brain stimulation in alleviating essential tremor is well-established, the underlying mechanisms of the treatment are unclear. Essential tremor, as characterized by tremor during action, is proposed to be driven by a dysfunction in the cerebello-thalamo-cerebral circuit that is evident not only during motor actions but also during rest. Stimulation effects on resting-state functional connectivity were investigated by functional MRI in 16 essential tremor patients with fully implanted deep brain stimulation in the caudal zona incerta during On-and-Off therapeutic stimulation, in a counterbalanced design. Functional connectivity was calculated between different constellations of sensorimotor as well as non-sensorimotor regions (as derived from seed-based and data-driven approaches), and compared between On and Off stimulation. We found that deep brain stimulation did not modulate resting-state functional connectivity. The lack of modulation by deep brain stimulation during resting-state, in combination with previously demonstrated effects on the cerebello-thalamo-cerebral circuit during motor tasks, suggests an action-dependent modulation of the stimulation in essential tremor.

    Download full text (pdf)
    fulltext
  • 24.
    Baldvinsdóttir, Bryndís
    et al.
    Department of Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden.
    Klurfan, Paula
    Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden.
    Eneling, Johanna
    Department of Clinical Sciences, Linköping University, Linköping, Sweden.
    Ronne-Engström, Elisabeth
    Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
    Enblad, Per
    Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
    Lindvall, Peter
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Aineskog, Helena
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Friðriksson, Steen
    Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden.
    Svensson, Mikael
    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
    Alpkvist, Peter
    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
    Hillman, Jan
    Department of Clinical Sciences, Linköping University, Linköping, Sweden.
    Kronvall, Erik
    Department of Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden.
    Nilsson, Ola G.
    Department of Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden.
    Adverse events during endovascular treatment of ruptured aneurysms: a prospective nationwide study on subarachnoid hemorrhage in sweden2023In: Brain and Spine, ISSN 2772-5294, Vol. 3, article id 102708Article in journal (Refereed)
    Abstract [en]

    Introduction: A range of adverse events (AEs) may occur in patients with subarachnoid hemorrhage (SAH). Endovascular treatment is commonly used to prevent aneurysm re-rupture.

    Research question: The aim of this study was to identify AEs related to endovascular treatment, analyze risk factors for AEs and how AEs affect patient outcome.

    Material and methods: Patients with aneurysmal SAH admitted to all neurosurgical centers in Sweden during a 3.5-year period (2014–2018) were prospectively registered. AEs related to endovascular aneurysm treatment were thromboembolic events, aneurysm re-rupture, vessel dissection and puncture site hematoma. Potential risk factors for the AEs were analyzed using multivariate logistic regression. Functional outcome was assessed at one year using the extended Glasgow outcome scale.

    Results: In total, 1037 patients were treated for ruptured aneurysms. Of which, 715 patients were treated with endovascular occlusion. There were 115 AEs reported in 113 patients (16%). Thromboembolic events were noted in 78 patients (11%). Aneurysm re-rupture occurred in 28 (4%), vessel dissection in 4 (0.6%) and puncture site hematoma in 5 (0.7%). Blister type aneurysm, aneurysm smaller than 5 mm and endovascular techniques other than coiling were risk factors for treatment-related AEs. At follow-up, 230 (32%) of the patients had unfavorable outcome. Patients suffering intraprocedural aneurysm re-rupture were more likely to have unfavorable outcome (OR 6.9, 95% CI 2.3–20.9).

    Discussion and conclusion: Adverse events related to endovascular occlusion of a ruptured aneurysm were seen in 16% of patients. Aneurysm re-rupture during endovascular treatment was associated with increased risk of unfavorable functional outcome.

    Download full text (pdf)
    fulltext
  • 25.
    Baldvinsdóttir, Bryndís
    et al.
    Department of Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden.
    Kronvall, Erik
    Department of Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden.
    Ronne-Engström, Elisabeth
    Department of Medical Sciences, Neurosurgery, Uppsala University, Uppsala, Sweden.
    Enblad, Per
    Department of Medical Sciences, Neurosurgery, Uppsala University, Uppsala, Sweden.
    Lindvall, Peter
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Aineskog, Helena
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Friðriksson, Steen
    Department of Clinical Neuroscience, Neurosurgery, University of Gothenburg, Gothenburg, Sweden.
    Klurfan, Paula
    Department of Clinical Neuroscience, Neurosurgery, University of Gothenburg, Gothenburg, Sweden.
    Svensson, Mikael
    Department of Clinical Neuroscience, Neurosurgery, Karolinska Institute, Stockholm, Sweden.
    Alpkvist, Peter
    Department of Clinical Neuroscience, Neurosurgery, Karolinska Institute, Stockholm, Sweden.
    Hillman, Jan
    Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
    Eneling, Johanna
    Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
    Nilsson, Ola G
    Department of Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden.
    Adverse events associated with microsurgial treatment for ruptured intracerebral aneurysms: A prospective nationwide study on subarachnoid haemorrhage in Sweden2023In: Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, E-ISSN 1468-330X, Vol. 94, no 7, p. 575-580Article in journal (Refereed)
    Abstract [en]

    Background: Adverse events (AEs) or complications may arise secondary to the treatment of aneurysmal subarachnoid haemorrhage (SAH). The aim of this study was to identify AEs associated with microsurgical occlusion of ruptured aneurysms, as well as to analyse their risk factors and impact on functional outcome.

    Methods: Patients with aneurysmal SAH admitted to the neurosurgical centres in Sweden were prospectively registered during a 3.5-year period (2014-2018). AEs were categorised as intraoperative or postoperative. A range of variables from patient history and SAH characteristics were explored as potential risk factors for an AE. Functional outcome was assessed approximately 1 year after the bleeding using the extended Glasgow Outcome Scale.

    Results: In total, 1037 patients were treated for ruptured aneurysms, of which, 322 patients were treated with microsurgery. There were 105 surgical AEs in 97 patients (30%); 94 were intraoperative AEs in 79 patients (25%). Aneurysm rerupture occurred in 43 patients (13%), temporary occlusion of the parent artery >5 min in 26 patients (8%) and adjacent vessel injury in 25 patients (8%). High Fisher grade and brain oedema on CT were related to increased risk of AEs. At follow-up, 38% of patients had unfavourable outcome. Patients suffering AEs were more likely to have unfavourable outcome (OR 2.3, 95% CI 1.10 to 4.69).

    Conclusion: Intraoperative AEs occurred in 25% of patients treated with microsurgery for ruptured intracerebral aneurysm in this nationwide survey. Although most operated patients had favourable outcome, AEs were associated with increased risk of unfavourable outcome.

  • 26.
    Behzadi, Arvin
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Biomarkers for diagnosis and prognosis in amyotrophic lateral sclerosis2024Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to paresis, muscle atrophy, and respiratory failure. ALS can be difficult to diagnose and prognosticate early.

    Aim: To investigate the diagnostic and prognostic characteristics of biomarkers in cerebrospinal fluid (CSF), plasma, and skeletal muscle tissue in patients with ALS.

    Paper I: Neurofilament light chain (NFL) and phosphorylated neurofilament heavy chain (pNFH) were analyzed in CSF using enzyme-linked immunosorbent assay (ELISA), and NFL in plasma was analyzed using single-molecule array (SIMOA). CSF NFL, CSF pNFH, and plasma NFL concentrations can differentiate ALS patients from ALS mimics, and were significantly negatively correlated with the disease duration in ALS patients.

    Paper II: Myosin heavy chain (MyHC) isoforms in extraocular muscles were investigated using immunofluorescence. Control donors had significantly higher proportion of myofibers containing MyHCIIa and significantly lower proportion of myofibers containing MyHCeom in the global layer compared to spinal-onset ALS and bulbar-onset ALS donors. Disease duration in the spinal-onset ALS donors was significantly correlated with the proportion of myofibers containing MyHCIIa in the global layer and MyHCeom in the orbital layer.

    Paper III: The study combined the neurofilament concentrations from Paper I, with cytokines previously analyzed in CSF and plasma using SIMOA, to investigate distinct molecular phenotypes in ALS. Patients with bulbar-onset ALS had significantly higher concentrations of CSF tumor necrosis factor α (TNF-α) compared to ALS mimics. TNF-α and NFL were significantly correlated with each other in both CSF and plasma in ALS patients. Combined analysis of NFL and IL-6 in plasma identified molecular prognostic subgroups in ALS patients.

    Paper IV: Creatine kinase (CK), high-sensitivity cardiac troponin T (hs-cTnT), hs-cTnI, and cystatin C (CysC) were analyzed in plasma in a fully accredited laboratory. CK and hs-cTnT concentrations were significantly elevated in limb-onset ALS compared to controls and bulbar-onset ALS. hs-cTnT concentrations were significantly elevated in truncal-onset ALS compared to controls and bulbar-onset ALS. Multivariable Cox proportional hazards models indicated elevated concentrations of CysC as a significant marker for worse prognosis in ALS.

    Conclusions: The papers report diagnostic and prognostic characteristics of biomarkers in CSF, plasma, and muscle tissue in ALS patients. The significant findings for biomarkers in plasma could be of value since plasma sampling does not involve a lumbar puncture.

    Download full text (pdf)
    Fulltext
    Download (pdf)
    Spikblad
    Download (jpg)
    presentationsbild
  • 27.
    Behzadi, Arvin
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Olesen, Mads Nikolaj
    Pujol-Calderón, Fani
    Tjust, Anton E.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Wuolikainen, Anna
    Umeå University, Faculty of Science and Technology, Department of Chemistry.
    Madsen, Jonna Skov
    Brandslund, Ivan
    Blennow, Kaj
    Zetterberg, Henrik
    Asgari, Nasrin
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Forsberg, Karin
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Combined analysis of neurofilament light chain and interleukin 6 in plasma reveals distinct molecular phenotypes in ALS and can differentiate ALS patients into prognostic subgroupsManuscript (preprint) (Other academic)
  • 28.
    Behzadi, Arvin
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Pujol-Calderón, Fani
    Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
    Tjust, Anton E.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Wuolikainen, Anna
    Umeå University, Faculty of Science and Technology, Department of Chemistry.
    Höglund, Kina
    Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
    Forsberg, Karin
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Portelius, Erik
    Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
    Blennow, Kaj
    Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
    Zetterberg, Henrik
    Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics2021In: Scientific Reports, E-ISSN 2045-2322, Vol. 11, no 1, article id 22128Article in journal (Refereed)
    Abstract [en]

    Delayed diagnosis and misdiagnosis are frequent in people with amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). Neurofilament light chain (NFL) and phosphorylated neurofilament heavy chain (pNFH) are elevated in ALS patients. We retrospectively quantified cerebrospinal fluid (CSF) NFL, CSF pNFH and plasma NFL in stored samples that were collected at the diagnostic work-up of ALS patients (n = 234), ALS mimics (n = 44) and controls (n = 9). We assessed the diagnostic performance, prognostication value and relationship to the site of onset and genotype. CSF NFL, CSF pNFH and plasma NFL levels were significantly increased in ALS patients compared to patients with neuropathies & myelopathies, patients with myopathies and controls. Furthermore, CSF pNFH and plasma NFL levels were significantly higher in ALS patients than in patients with other MNDs. Bulbar onset ALS patients had significantly higher plasma NFL levels than spinal onset ALS patients. ALS patients with C9orf72HRE mutations had significantly higher plasma NFL levels than patients with SOD1 mutations. Survival was negatively correlated with all three biomarkers. Receiver operating characteristics showed the highest area under the curve for CSF pNFH for differentiating ALS from ALS mimics and for plasma NFL for estimating ALS short and long survival. All three biomarkers have diagnostic value in differentiating ALS from clinically relevant ALS mimics. Plasma NFL levels can be used to differentiate between clinical and genetic ALS subgroups.

    Download full text (pdf)
    fulltext
  • 29.
    Behzadi, Arvin
    et al.
    Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB). Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Tjust, Anton Erik
    Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB). Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Liu, Jing-Xia
    Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB).
    Andersen, Peter Munch
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Brännström, Thomas
    Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology. https://orcid.org/0000-0002-4201-8204.
    Pedrosa Domellöf, Fatima
    Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB). Umeå University, Faculty of Medicine, Department of Clinical Sciences, Ophthalmology.
    Myofiber type shift in extraocular muscles in amyotrophic lateral sclerosis2023In: Investigative Ophthalmology and Visual Science, ISSN 0146-0404, E-ISSN 1552-5783, Vol. 64, no 5, article id 15Article in journal (Refereed)
    Abstract [en]

    Purpose: To investigate changes in myofiber composition in the global layer (GL) and orbital layer (OL) of extraocular muscles (EOMs) from terminal amyotrophic lateral sclerosis (ALS) donors.

    Methods: Medial recti muscles collected postmortem from spinal-onset ALS, bulbar-onset ALS, and healthy control donors were processed for immunofluorescence with antibodies against myosin heavy chain (MyHC) IIa, MyHCI, MyHCeom, laminin, neurofilaments, synaptophysin, acetylcholine receptor γ-subunit, and α-bungarotoxin.

    Results: The proportion of myofibers containing MyHCIIa was significantly smaller and MyHCeom was significantly larger in the GL of spinal-onset ALS and bulbar-onset ALS donors compared to control donors. Changes in the GL were more prominent in the bulbar-onset ALS donors, with a significantly larger proportion of myofibers containing MyHCeom being present compared to spinal-onset ALS donors. There were no significant differences in the myofiber composition in the OL. In the spinal-onset ALS donors, the proportions of myofibers containing MyHCIIa in the GL and MyHCeom in the OL were significantly correlated with the disease duration. Neurofilament and synaptophysin were present at motor endplates of myofibers containing MyHCeom in ALS donors.

    Conclusions: The EOMs of terminal ALS donors displayed changes in the fast-type myofiber composition in the GL, with a more pronounced alteration in bulbar-onset ALS donors. Our results align with the worse prognosis and subclinical changes in eye movement function previously observed in bulbar-onset ALS patients and suggest that the myofibers in the OL might be more resistant to the pathological process in ALS.

    Download full text (pdf)
    fulltext
  • 30.
    Behzadi, Arvin
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Wuolikainen, Anna
    Umeå University, Faculty of Science and Technology, Department of Chemistry.
    Tjust, Anton E.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Forsberg, Karin
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Weydt, Patrick
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Cardiac troponin T, cystatin C and creatine kinase as biomarkers in clinical phenotypes, genotypes and prognostication in amyotrophic lateral sclerosisManuscript (preprint) (Other academic)
  • 31. Benatar, Michael
    et al.
    Granit, Volkan
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Grignon, Anne-Laure
    McHutchison, Caroline
    Cosentino, Stephanie
    Malaspina, Andrea
    Wuu, Joanne
    Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity2022In: Brain, ISSN 0006-8950, E-ISSN 1460-2156, Vol. 145, no 10, p. 3500-3508Article in journal (Refereed)
    Abstract [en]

    Amyotrophic lateral sclerosis, when viewed as a biological entity rather than a clinical syndrome, probably evolves along a continuum, with the initial clinically silent phase eventually evolving into clinically manifest amyotrophic lateral sclerosis. Since motor neuron degeneration is incremental and cumulative over time, it stands to reason that the clinical syndrome of amyotrophic lateral sclerosis is probably preceded by a prodromal state characterized by minor motor abnormalities that are initially insufficient to permit a diagnosis of amyotrophic lateral sclerosis. This prodromal period, however, is usually missed, given the invariably long delays between symptom onset and diagnostic evaluation. The Pre-Symptomatic Familial ALS Study, a cohort study of pre-symptomatic gene mutation carriers, offers a unique opportunity to observe what is typically unseen. Here we describe the clinical characterization of 20 pre-symptomatic mutation carriers (in SOD1, FUS and C9orf72) whose phenoconversion to clinically manifest disease has been prospectively studied. In so doing, we observed a prodromal phase of mild motor impairment in 11 of 20 phenoconverters. Among the n = 12 SOD1 A4V mutation carriers, phenoconversion was characterized by abrupt onset of weakness, with a short (1-3.5 months) prodromal period observable in a small minority (n = 3); the observable prodrome invariably involved the lower motor neuron axis. By contrast, in all n = 3 SOD1 I113T mutation carriers, diffuse lower motor neuron and upper motor neuron signs evolved insidiously during a prodromal period that extended over a period of many years; prodromal manifestations eventually coalesced into a clinical syndrome that is recognizable as amyotrophic lateral sclerosis. Similarly, in all n = 3 C9orf72 hexanucleotide repeat expansion mutation carriers, focal or multifocal manifestations of disease evolved gradually over a prodromal period of 1-2 years. Clinically manifest ALS also emerged following a prodromal period of mild motor impairment, lasting >4 years and similar to 9 months, respectively, in n = 2 with other gene mutations (SOD1 L106V and FUS c.521del6). On the basis of this empirical evidence, we conclude that mild motor impairment is an observable state that precedes clinically manifest disease in three of the most common genetic forms of amyotrophic lateral sclerosis (SOD1, FUS, C9orf72), and perhaps in all genetic amyotrophic lateral sclerosis; we also propose that this might be true of non-genetic amyotrophic lateral sclerosis. As a diagnostic label, mild motor impairment provides the language to describe the indeterminate (and sometimes intermediate) transition between the unaffected state and clinically manifest amyotrophic lateral sclerosis. Recognizing mild motor impairment as a distinct clinical entity should generate fresh urgency for developing biomarkers reflecting the earliest events in the degenerative cascade, with potential to reduce the diagnostic delay and to permit earlier therapeutic intervention. Having observed ALS phenoconversion in 20 pre-symptomatic gene mutation carriers, Benatar et al. conclude that a prodromal period of mild motor impairment (MMI) precedes many (if not most) forms of ALS. They highlight the implications for reducing diagnostic delay and for early therapeutic intervention.

    Download full text (pdf)
    fulltext
  • 32.
    Benatar, Michael
    et al.
    Department of Neurology, University of Miami Miller School of Medicine, FL, Miami, United States.
    Hansen, Thomas
    Orphazyme, Copenhagen, Denmark.
    Rom, Dror
    Prosoft Clinical, PA, Chesterbrook, United States.
    Geist, Marie A
    Orphazyme, Copenhagen, Denmark.
    Blaettler, Thomas
    Orphazyme, Copenhagen, Denmark.
    Camu, William
    Department of Neurology University of Montpellier, CHU Montpellier, INM INSERM, Montpellier, France.
    Kuzma-Kozakiewicz, Magdalena
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
    van den Berg, Leonard H
    Department of Neurology, University Medical Center Utrecht, Utrecht, Netherlands.
    Morales, Raul Juntas
    Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.
    Chio, Adriano
    Rita Levi Montalcini Department of Neuroscience, University of Torino, Torino, Italy.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Pradat, Pierre-Francois
    APHP, Department of Neurology, Hôpital Pitié-Salpêtrière, Paris, France.
    Lange, Dale
    Department of Neurology, Hospital for Special Surgery, NY, New York, United States.
    Van Damme, Philip
    Department of Neurology, University Hospital Leuven, KU Leuven, Leuven, Belgium.
    Mora, Gabriele
    Istituti Clinici Scientifici Maugeri, IRCCS Milano, Milan, Italy.
    Grudniak, Mariusz
    Research and Development Department, Polish Stem Cell Bank, Warsaw, Poland.
    Elliott, Matthew
    University of Virginia Medical Center, VA, Charlottesville, United States.
    Petri, Susanne
    Department of Neurology, Hannover Medical School, Hannover, Germany.
    Olney, Nicholas
    Providence Portland Medical Center, Providence Brain and Spine Institute, OR, Portland, United States.
    Ladha, Shafeeq
    Department of Neurology, Barrow Neurological Institute, AZ, Phoenix, United States.
    Goyal, Namita A
    Department of Neurology, University of California Irvine, CA, Irvine, United States.
    Meyer, Thomas
    Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
    Hanna, Michael G
    University College London, National Hospital for Neurology and Neurosurgery, London, United Kingdom.
    Quinn, Colin
    Department of Neurology, Perelman School of Medicine, University of Pennsylvania, PA, Philadelphia, United States.
    Genge, Angela
    Department of Neurology, Montreal Neurological Institute, QC, Montreal, Canada.
    Zinman, Lorne
    Sunnybrook Health Sciences Centre, ON, Toronto, Canada.
    Jabari, Duaa
    Department of Neurology, The University of Kansas Medical Center, KS, Kansas City, United States.
    Shoesmith, Christen
    Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, ON, London, Canada.
    Ludolph, Albert C
    Department of Neurology, University of Ulm, Ulm, Germany.
    Neuwirth, Christoph
    Neuromuscular Disease Unit/ALS Clinic, Kantonspital St Gallen, St Gallen, Switzerland.
    Nations, Sharon
    University of Texas Southwestern, TX, Dallas, United States.
    Shefner, Jeremy M
    Department of Neurology, Barrow Neurological Institute, AZ, Phoenix, United States.
    Turner, Martin R
    Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
    Wuu, Joanne
    Department of Neurology, University of Miami Miller School of Medicine, FL, Miami, United States.
    Bennett, Richard
    Orphazyme, Copenhagen, Denmark.
    Dang, Hoang
    Orphazyme, Copenhagen, Denmark.
    Sundgreen, Claus
    Orphazyme, Copenhagen, Denmark.
    Granit, Volkan
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Steele, Julie
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Levy, Wendy
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Paredes, Maria Elena
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Hernandez, Jessica
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Bilsker, Martin
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Szacka, Katarzyna
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Ronert, Adam
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Jablońska, Dorota
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Łuczak, Alina Zuzanna
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Chaverri, Delia
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Janse van Mantgem, Mark R
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Bunte, Tommy M
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Broere, Bianca
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    de Fockert, Arianne
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Sanchez-Tejerina, Daniel
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Landabaso, Carmen
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Calvo, Andrea
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Moglia, Cristina
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Manera, Umberto
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Canosa, Antonio
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Vasta, Rosario
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Salamone, Paolina
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Fuda, Giuseppe
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    DeMarco, Giovanni
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Casale, Federico
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    ME Forsberg, Karin
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Winroth, Ivar
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Almgren Stenberg, Erica
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Holmgren, Monica
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Amador, Maria del Mar
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Lenglet, Timothee
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Querin, Giorgia
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Coudoin, Sylvie
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Pavlakis, Pantelis
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Holzberg, Shara
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Sideri, Riccardo
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Marinou, Kalliopi
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Czarnecki, Maciej
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Ługiewicz, Renata
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Biel-Czarnecka, Marta
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Boczkowska, Marcelina
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Schotte, Caroline
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Vynckier, Jan
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Van Daele, Sien
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Claeys, Thomas
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Delmotte, Koen
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Swinnen, Bart
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Serrien, Anouk
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    D'Hondt, Ann
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Lamaire, Nikita
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Debien, Elisa
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Jones, Sarah
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Vachon, Chris
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Grogan, James
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Solorzano, Guillermo
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Crowell, Allison
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Rakocevic, Goran
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Wagoner, Mary
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Alma, Osmanovic
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Flavia, Wiehler
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Sonja, Körner
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Olivia, Schreiber-Katz
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Camilla, Wohnrade
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Anastasia, Sarikidi
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Carola, Kassebaum
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Chantal, Fischer
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Adamo, Ashley
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Turcotte, Nicole
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Duncan, Jessie
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Turner, Ivone
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Elman, Lauren
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Massie, Rami
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Berube, Maxime
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Saunders, Natalie
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Salmon, Kristiana
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Foucher, Juliette
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Agessandro, Abrahao
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Shirley, Pham
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Jahan, Mookshah
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Phung, Liane
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Statland, Jeffrey
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Jawdat, Omar
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Dimachkie, Mazen
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Pasnoor, Mamatha
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Farmakidis, Constantine
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Heim, Andrew
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Lillig, Katie
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Lackey, Alyssa
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Weber, Markus
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Kurz, Martina
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Levine, Todd
    [NO CONNECTION TO ANY AFFILIATION IN XML].
    Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial2024In: Lancet Neurology, ISSN 1474-4422, E-ISSN 1474-4465, Vol. 23, no 7, p. 687-699Article in journal (Refereed)
    Abstract [en]

    Background: Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral sclerosis, with multiple mechanisms of action, including clearance of protein aggregates, a pathological hallmark of sporadic and familial amyotrophic lateral sclerosis. We aimed to evaluate the safety and efficacy of arimoclomol in patients with amyotrophic lateral sclerosis.

    Methods: ORARIALS-01 was a multinational, randomised, double-blind, placebo-controlled, parallel-group trial done at 29 centres in 12 countries in Europe and North America. Patients were eligible if they were aged 18 years or older and met El Escorial criteria for clinically possible, probable, probable laboratory-supported, definite, or familial amyotrophic lateral sclerosis; had an ALS Functional Rating Scale-Revised score of 35 or more; and had slow vital capacity at 70% or more of the value predicted on the basis of the participant's age, height, and sex. Patients were randomly assigned (2:1) in blocks of 6, stratified by use of a stable dose of riluzole or no riluzole use, to receive oral arimoclomol citrate 1200 mg/day (400 mg three times per day) or placebo. The Randomisation sequence was computer generated centrally. Investigators, study personnel, and study participants were masked to treatment allocation. The primary outcome was the Combined Assessment of Function and Survival (CAFS) rank score over 76 weeks of treatment. The primary outcome and safety were analysed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03491462, and is completed.

    Findings: Between July 31, 2018, and July 17, 2019, 287 patients were screened, 245 of whom were enrolled in the trial and randomly assigned. The modified intention-to-treat population comprised 239 patients (160 in the arimoclomol group and 79 in the placebo group): 151 (63%) were male and 88 (37%) were female; mean age was 57·6 years (SD 10·9). CAFS score over 76 weeks did not differ between groups (mean 0·51 [SD 0·29] in the arimoclomol group vs 0·49 [0·28] in the placebo group; p=0·62). Cliff's delta comparing the two groups was 0·039 (95% CI –0·116 to 0·194). Proportions of participants who died were similar between the treatment groups: 29 (18%) of 160 patients in the arimoclomol group and 18 (23%) of 79 patients in the placebo group. Most deaths were due to disease progression. The most common adverse events were gastrointestinal. Adverse events were more often deemed treatment-related in the arimoclomol group (104 [65%]) than in the placebo group (41 [52%]) and more often led to treatment discontinuation in the arimoclomol group (26 [16%]) than in the placebo group (four [5%]).

    Interpretation: Arimoclomol did not improve efficacy outcomes compared with placebo. Although available biomarker data are insufficient to preclude future strategies that target the HSP response, safety data suggest that a higher dose of arimoclomol would not have been tolerated.

    Funding: Orphazyme.

  • 33.
    Benatar, Michael
    et al.
    Department of Neurology and ALS Center, University of Miami Miller School of Medicine, FL, Miami, United States.
    Robertson, Janice
    University of Toronto, Tanz Centre for Research in Neurodegenerative Diseases, Department of Laboratory Medicine and Pathobiology, ON, Toronto, Canada.
    Andersen, Peter Munch
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention2025In: Lancet Neurology, ISSN 1474-4422, E-ISSN 1474-4465, Vol. 24, no 1, p. 77-86Article, review/survey (Refereed)
    Abstract [en]

    Pathogenic variants in the superoxide dismutase 1 (SOD1) gene were the first identified genetic cause of amyotrophic lateral sclerosis (ALS), in 1993. This discovery enabled the development of transgenic rodent models for studying the biology of SOD1 ALS. The understanding that SOD1 ALS is driven by a toxic gain-of-function mutation has led to therapeutic strategies that aim to lower concentrations of SOD1 protein, an endeavour that has been complicated by the phenotypic heterogeneity of SOD1 ALS. The successful development of genetically targeted therapies to reduce SOD1 expression, together with a better understanding of pre-symptomatic disease and the discovery of neurofilament light protein as a susceptibility/risk biomarker that predicts phenoconversion, has ushered in a new era of trials that aim to prevent clinically manifest SOD1 ALS. The 30-year journey from gene discovery to gene therapy has not only uncovered the pathophysiology of SOD1 ALS, but has also facilitated the development of biomarkers that should aid therapy development for all forms of ALS.

  • 34.
    Benatar, Michael
    et al.
    Department of Neurology, University of Miami, FL, Miami, United States.
    Wuu, Joanne
    Department of Neurology, University of Miami, FL, Miami, United States.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Bucelli, Robert C.
    Washington University School of Medicine, MO, St. Louis, United States.
    Andrews, Jinsy A.
    The Neurological Institute, Columbia University Irving Medical Center, NY, New York, United States.
    Otto, Markus
    Department of Neurology, Martin Luther University, Halle-Wittenberg, Halle (Saale), Germany.
    Farahany, Nita A.
    Duke University School of Law, NC, Durham, United States.
    Harrington, Elizabeth A.
    Columbia University Irving Medical Center, NY, New York, United States.
    Chen, Weiping
    Biogen, MA, Cambridge, United States.
    Mitchell, Adele A.
    Biogen, MA, Cambridge, United States.
    Ferguson, Toby
    Biogen, MA, Cambridge, United States.
    Chew, Sheena
    Biogen, MA, Cambridge, United States.
    Gedney, Liz
    Biogen, MA, Cambridge, United States.
    Oakley, Sue
    Biogen, MA, Cambridge, United States.
    Heo, Jeong
    Biogen, MA, Cambridge, United States.
    Chary, Sowmya
    Biogen, MA, Cambridge, United States.
    Fanning, Laura
    Biogen, MA, Cambridge, United States.
    Graham, Danielle
    Biogen, MA, Cambridge, United States.
    Sun, Peng
    Biogen, MA, Cambridge, United States.
    Liu, Yingying
    Biogen, MA, Cambridge, United States.
    Wong, Janice
    Biogen, MA, Cambridge, United States.
    Fradette, Stephanie
    Biogen, MA, Cambridge, United States.
    Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the Atlas study2022In: Neurotherapeutics, ISSN 1933-7213, Vol. 19, p. 1248-1258Article in journal (Refereed)
    Abstract [en]

    Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream biological mechanisms of disease, and therapeutic interventions are usually administered relatively late in the course of disease. Genetic forms of ALS offer a unique opportunity for therapeutic development, as genetic associations may reveal potential insights into disease etiology. Genetic ALS may also be amenable to investigating earlier intervention given the possibility of identifying clinically presymptomatic, at-risk individuals with causative genetic variants. There is increasing evidence for a presymptomatic phase of ALS, with biomarker data from the Pre-Symptomatic Familial ALS (Pre-fALS) study showing that an elevation in blood neurofilament light chain (NfL) precedes phenoconversion to clinically manifest disease. Tofersen is an investigational antisense oligonucleotide designed to reduce synthesis of superoxide dismutase 1 (SOD1) protein through degradation of SOD1 mRNA. Informed by Pre-fALS and the tofersen clinical development program, the ATLAS study (NCT04856982) is designed to evaluate the impact of initiating tofersen in presymptomatic carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression who also have biomarker evidence of disease activity (elevated plasma NfL). The ATLAS study will investigate whether tofersen can delay the emergence of clinically manifest ALS. To our knowledge, ATLAS is the first interventional trial in presymptomatic ALS and has the potential to yield important insights into the design and conduct of presymptomatic trials, identification, and monitoring of at-risk individuals, and future treatment paradigms in ALS.

    Download full text (pdf)
    fulltext
  • 35.
    Benatar, Michael
    et al.
    Department of Neurology, Miller School of Medicine, University of Miami, FL, Miami, United States.
    Wuu, Joanne
    Department of Neurology, Miller School of Medicine, University of Miami, FL, Miami, United States.
    Huey, Edward D.
    Department of Psychiatry and Human Behaviour, Alpert Medical School of Brown University, RI, Providence, United States.
    McMillan, Corey T.
    Department of Neurology, University of Pennsylvania Perelman School of Medicine, PA, Philadelphia, United States.
    Petersen, Ronald C.
    Department of Neurology, Mayo Clinic, MN, Rochester, United States.
    Postuma, Ronald
    Department of Neurology, Montreal Neurological Institute, McGill University, QC, Montreal, Canada.
    McHutchison, Caroline
    Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom; Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, United Kingdom.
    Dratch, Laynie
    Department of Neurology, University of Pennsylvania Perelman School of Medicine, PA, Philadelphia, United States.
    Arias, Jalayne J.
    Department of Health Policy & Behavioral Sciences, School of Public Health, Georgia State University, GA, Atlanta, United States.
    Crawley, Anita
    NY, Buffalo, United States.
    Houlden, Henry
    UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
    McDermott, Michael P.
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY, Rochester, United States; Department of Neurology, University of Rochester School of Medicine and Dentistry, NY, Rochester, United States.
    Cai, Xueya
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY, Rochester, United States.
    Thakur, Neil
    ALS Association, VA, Arlington, United States.
    Boxer, Adam
    Department of Neurology, University of California, CA, San Francisco, United States.
    Rosen, Howard
    Department of Neurology, University of California, CA, San Francisco, United States.
    Boeve, Bradley F.
    Department of Neurology, Mayo Clinic, MN, Rochester, United States.
    Dacks, Penny
    Association for Frontotemporal Degeneration, PA, King of Prussia, United States.
    Cosentino, Stephanie
    Department of Psychiatry, Columbia University, New York, NY, USA.
    Abrahams, Sharon
    Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom; Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, United Kingdom.
    Shneider, Neil
    Department of Neurology, Columbia University, New York, NY, USA.
    Lingor, Paul
    Department of Neurology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
    Shefner, Jeremy
    Department of Neurology, Barrow Neurological Institute, AZ, Phoenix, United States.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Al-Chalabi, Ammar
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom; Department of Neurology, King's College Hospital, London, United Kingdom.
    Turner, Martin R.
    Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
    The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology2024In: Nature Reviews Neurology, ISSN 1759-4758, E-ISSN 1759-4766, Vol. 20, no 6, p. 364-376Article, review/survey (Refereed)
    Abstract [en]

    Increasing appreciation of the phenotypic and biological overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence for a pre-symptomatic stage of disease and observations that this stage of disease might not always be clinically silent, is challenging traditional views of these disorders. These advances have highlighted the need to adapt ingrained notions of these clinical syndromes to include both the full phenotypic continuum - from clinically silent, to prodromal, to clinically manifest - and the expanded phenotypic spectrum that includes ALS, frontotemporal dementia and some movement disorders. The updated clinical paradigms should also align with our understanding of the biology of these disorders, reflected in measurable biomarkers. The Miami Framework, emerging from discussions at the Second International Pre-Symptomatic ALS Workshop in Miami (February 2023; a full list of attendees and their affiliations appears in the Supplementary Information) proposes a classification system built on: first, three parallel phenotypic axes - motor neuron, frontotemporal and extrapyramidal - rather than the unitary approach of combining all phenotypic elements into a single clinical entity; and second, biomarkers that reflect different aspects of the underlying pathology and biology of neurodegeneration. This framework decouples clinical syndromes from biomarker evidence of disease and builds on experiences from other neurodegenerative diseases to offer a unified approach to specifying the pleiotropic clinical manifestations of disease and describing the trajectory of emergent biomarkers.

  • 36.
    Benatar, Michael
    et al.
    Department of Neurology, University of Miami, FL, Miami, United States.
    Wuu, Joanne
    Department of Neurology, University of Miami, FL, Miami, United States.
    McHutchison, Caroline
    Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom; Euan MacDonald Centre for Mnd Research, University of Edinburgh, Edinburgh, United Kingdom.
    Postuma, Ronald B
    Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Canada.
    Boeve, Bradley F
    Department of Neurology, Mayo Clinic, MN, Rochester, United States.
    Petersen, Ronald
    Department of Neurology, Mayo Clinic, MN, Rochester, United States.
    Ross, Christopher A
    Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, School of Medicine, MD, Baltimore, United States; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, MD, Baltimore, United States; Department of Pharmacology and Molecular Sciences, Johns Hopkins University, School of Medicine, MD, Baltimore, United States; Department of Neurology, Johns Hopkins University, School of Medicine, MD, Baltimore, United States.
    Rosen, Howard
    Department of Neurology, University of California San Francisco, CA, United States.
    Arias, Jalayne J
    Department of Neurology, University of California San Francisco, CA, United States.
    Fradette, Stephanie
    Biogen, MA, Cambridge, United States.
    McDermott, Michael P
    Department of Biostatistics and Computational Biology, University of Rochester, School of Medicine and Dentistry, NY, Rochester, United States; Department of Neurology, University of Rochester, School of Medicine and Dentistry, NY, Rochester, United States.
    Shefner, Jeremy
    Department of Neurology, Barrow Neurological Institute, AZ, Phoenix, United States.
    Stanislaw, Christine
    Department of Human Genetics, Emory University, GA, Atlanta, United States.
    Abrahams, Sharon
    Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom; Euan MacDonald Centre for Mnd Research, University of Edinburgh, Edinburgh, United Kingdom.
    Cosentino, Stephanie
    Department of Psychiatry, Columbia University, NY, New York, United States.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Finkel, Richard S
    Department of Pediatric Medicine, Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, TN, Memphis, United States.
    Granit, Volkan
    Department of Neurology, University of Miami, FL, Miami, United States.
    Grignon, Anne-Laure
    Department of Neurology, University of Miami, FL, Miami, United States.
    Rohrer, Jonathan D
    Department of Neurodegenerative Disease, Dementia Research Centre, Ucl Institute of Neurology, Queen Square, London, United Kingdom.
    McMillan, Corey T
    Department of Neurology, University of Pennsylvania Perelman, School of Medicine, PA, Philadelphia, United States.
    Grossman, Murray
    Department of Neurology, University of Pennsylvania Perelman, School of Medicine, PA, Philadelphia, United States.
    Al-Chalabi, Ammar
    Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom; Department of Neurology, King's College Hospital, London, United Kingdom.
    Turner, Martin R
    Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
    First International Pre-Symptomatic ALS Workshop,
    Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases2022In: Brain, ISSN 0006-8950, E-ISSN 1460-2156, Vol. 145, no 1, p. 27-44Article, review/survey (Refereed)
    Abstract [en]

    Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer's disease, Parkinson's disease, Huntington's disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer's disease based on inferred underlying histopathology. Parkinson's disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington's disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned - more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers - we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.

    Download full text (pdf)
    fulltext
  • 37.
    Ben-Shabat, Ilan
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Darehed, David
    Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine.
    Eriksson, Marie
    Umeå University, Faculty of Social Sciences, Umeå School of Business and Economics (USBE), Statistics.
    Salzer, Jonatan
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Characteristics of in-hospital stroke patients in Sweden: a nationwide register-based study2023In: European Stroke Journal, ISSN 2396-9873, E-ISSN 2396-9881, Vol. 8, no 3, p. 777-783Article in journal (Refereed)
    Abstract [en]

    INTRODUCTION: Few studies have reported the characteristics of patients with in-hospital stroke (IHS) including the reason for hospitalization and invasive procedures before the stroke. We aimed to extend current knowledge.

    PATIENTS AND METHODS: All adult patients with IHS in Sweden during 2010-2019 registered in the Swedish Stroke Register (Riksstroke) were included. The cohort was cross-linked to the National Patient Register and data extracted on background diagnoses, main discharge diagnoses, and procedure codes for the hospitalization when IHS occurred and any hospital-based healthcare contacts within 30 days before IHS.

    RESULTS: 231,402 stroke cases were identified of which 12,551 (5.4%) were in-hospital and had corresponding entries in the National Patient Register. Of the IHS patients, 11,420 (91.0%) had ischemic stroke and 1131 (9.0%) hemorrhagic stroke; 5860 (46.7%) of the IHS patients had at least one invasive procedure prior to ictus. 1696 (13.5%) had a cardiovascular procedure and 560 (4.5%) a neurosurgical procedure. 1319 (10.5%) patients only had minimally invasive procedures such as blood product transfusion, hemodialysis, or central line insertion. Common discharge diagnosis in patients with no invasive procedures were cardiovascular disorders, injuries, and respiratory disorders.

    DISCUSSION AND CONCLUSION: One in every 17 strokes in Sweden occur in a hospital. In this unselected large cohort the previously reported major causes for in-hospital stroke, cardiovascular and neurosurgical procedures, preceded IHS in only 18.0% of cases suggesting that other etiologies are more common than previously reported. Future studies should aim at determining absolute risks of stroke after surgical procedures and ways of risk reduction.

    Download full text (pdf)
    fulltext
  • 38.
    Ben-Shabat, Ilan
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Kvarnung, Malin
    Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
    Sperker, Wolfgang
    Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine.
    Bruhn, Helene
    Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden.
    Wredenberg, Anna
    Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden; Departments of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
    Wibom, Rolf
    Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden.
    Nennesmo, Inger
    Departments of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
    Engvall, Martin
    Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden; Departments of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
    Paucar, Martin
    Departments of Neurology, Karolinska Institutet, Stockholm, Sweden.
    Ataxia syndrome with hearing loss and nephronophthisis associated with a novel homozygous variant in XPNPEP32023In: Neurology: Genetics, E-ISSN 2376-7839, Vol. 9, no 6, article id e200100Article in journal (Refereed)
    Abstract [en]

    Objectives: Biallelic variants in XPNPEP3 are associated with a rare mitochondrial syndrome characterized by nephronophthisis leading to kidney failure, essential tremor, hearing loss, seizures, and intellectual disability. Only 2 publications on this condition are available. We report a man with a complex ataxia syndrome, hearing loss, and kidney failure associated with a new biallelic variant in XPNPEP3.

    Methods: Clinical evaluation, neuroimaging studies, a kidney biopsy, and whole genome sequencing (WGS) were applied. Since the phenotype was compatible with a mitochondrial disease, a muscle biopsy with morphological and mitochondrial biochemical investigations was performed.

    Results: Axial ataxia, cerebellar atrophy, hearing loss, myopathy, ptosis, supranuclear palsy, and kidney failure because of nephronophthisis were the prominent features in this case. WGS revealed the novel biallelic variant c.766C>T (p.Gln256*) in XPNPEP3. A muscle biopsy revealed COX negative fibers, a few ragged red fibers, and ultrastructural mitochondrial changes. Enzyme activity in respiratory chain complex IV was reduced in muscle and fibroblasts.

    Discussion: This is the first report of a slowly progressive cerebellar ataxia associated with a novel biallelic variant in XPNPEP3. Abnormalities typical for mitochondrial disease and the slow progression of kidney disease are also striking. Our report expands the spectrum of XPNPEP3-related diseases.

    Download full text (pdf)
    fulltext
  • 39.
    Ben-Shabat, Ilan
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Lindvall, Kristina
    Umeå University, Faculty of Medicine, Department of Epidemiology and Global Health.
    Salzer, Jonatan
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Exploring strategies for management of in-hospital stroke in Sweden: A qualitative study2024In: PLOS ONE, E-ISSN 1932-6203, Vol. 19, no 11, article id e0313765Article in journal (Refereed)
    Abstract [en]

    Background: Patients with in-hospital stroke (IHS) are discovered and treated with delays compared to community-onset stroke. This qualitative study explores current routines and clinical practices for IHS in Sweden, aiming to uncover factors influencing management and propose areas for future research and development.

    Methods: Six physicians in charge of stroke alerts at Swedish hospitals were individually interviewed in video calls. Informants were selected from The Swedish Stroke Register, based on the hospital-specific median processing time for delivering thrombolysis or thrombectomy to IHS patients, stratified by hospital size. Transcribed interviews were analysed using reflexive thematic analysis.

    Results: Three main themes were developed. The first emphasized the crucial step of discovering IHS and outlined possible workflow pathways, including defining the “key player” with stroke expertise and mandate to proceed with the stroke alert to immediate radiology. Subsequent themes addressed obstacles to optimal practice and suggested clear guidelines for contacting the "key player” to reduce delays, as well as offering IHS education to hospital staff.

    Conclusions: This study identified differences in workflows for IHS management across the six included sites. A "key player" emerged as a common denominator, who was called as the initiation of the stroke alert and had mandate to proceed with the alert to immediate radiology. Clear guidelines for contacting the “key player” and increased education about IHS were suggested as possible ways to mitigate delays to activate the stroke alert.

    Download full text (pdf)
    fulltext
  • 40.
    Berdynski, Mariusz
    et al.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences. Laboratory of Neurogenetics, Department of Neurodegenerative Disorders, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
    Miszta, Przemysław
    Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
    Safranow, Krzysztof
    Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 72 Powstańców Wlkp. Str., Szczecin, Poland.
    Andersen, Peter M.
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
    Morita, Mitsuya
    Division of Neurology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Japan.
    Filipek, Sławomir
    Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
    Żekanowski, Cezary
    Laboratory of Neurogenetics, Department of Neurodegenerative Disorders, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
    Kuźma-Kozakiewicz, Magdalena
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland; Neurodegenerative Diseases Research Group, Medical University of Warsaw, Warsaw, Poland.
    SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity2022In: Scientific Reports, E-ISSN 2045-2322, Vol. 12, no 1, article id 103Article in journal (Refereed)
    Abstract [en]

    Mutations in superoxide dismutase 1 gene (SOD1) are linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder predominantly affecting upper and lower motor neurons. The clinical phenotype of ALS shows inter- and intrafamilial heterogeneity. The aim of the study was to analyze the relations between individual SOD1 mutations and the clinical presentation using in silico methods to assess the SOD1 mutations severity. We identified SOD1 causative variants in a group of 915 prospectively tested consecutive Polish ALS patients from a neuromuscular clinical center, performed molecular modeling of mutated SOD1 proteins and in silico analysis of mutation impact on clinical phenotype and survival analysis of associations between mutations and hazard of clinical end-points. Fifteen SOD1 mutations were identified in 21.1% familial and 2.3% sporadic ALS cases. Their effects on SOD1 protein structure and functioning inferred from molecular modeling and in silico analyses correlate well with the clinical data. Molecular modeling results support the hypothesis that folding intermediates rather than mature SOD1 protein give rise to the source of cytotoxic conformations in ALS. Significant associations between type of mutation and clinical end-points were found.

    Download full text (pdf)
    fulltext
  • 41.
    Bergman, Joakim
    Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.